EU H2020 Project "ZIKAVAX (Fast track development of a Zika vaccine based on measles vector)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/207210/index.html

ZIKAVAX project word cloud

Explore the words cloud of the ZIKAVAX project. It provides you a very rough idea of what is the project "ZIKAVAX" about.

institut pasteur borns world vaccine yield diseases infection health preclinical disease clinical bioscience immunisation issue demonstrated zika public energie severe emergency adaptability 1947 commissariat proof malformations committed give recombinant mice rapid nor volunteers primates adult antigen treatments preventive infectious expression purity safety platform track brain epidemiological safe affordable congenital regions record model trial measles humans mosquito ultimate manufacturing truly atomique consequently zikavax urgent adults candidate agrave spread vector themis flavivirus date standard neurological variety unaffected vaccines declared virus organization therapies demonstration complications borne effectiveness innovative pathogens previously immunogenicity isolated human ia outbreak

Project "ZIKAVAX" data sheet

The following table provides information about the project.

Coordinator	EUROPEAN VACCINE INITIATIVE EWIV Organization address address: VOSSSTRASSE 2 GEB 4040 city: HEIDELBERG postcode: 69115 website: http://www.euvaccine.eu/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.zikavax.eu
Total cost	4˙918˙137 €
EC max contribution	4˙918˙137 € (100%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-10-01 to 2020-09-30

#	participants	country	role	EC contrib. [€]
1	EUROPEAN VACCINE INITIATIVE EWIV	DE (HEIDELBERG)	coordinator	673˙968.00
2	THEMIS BIOSCIENCE GMBH	AT (WIEN)	participant	3˙192˙862.00
3	INSTITUT PASTEUR	FR (PARIS CEDEX 15)	participant	562˙290.00
4	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES	FR (PARIS 15)	participant	489˙016.00

EUROPEAN VACCINE INITIATIVE EWIV

DE (HEIDELBERG)

coordinator

673˙968.00

THEMIS BIOSCIENCE GMBH

AT (WIEN)

participant

3˙192˙862.00

INSTITUT PASTEUR

FR (PARIS CEDEX 15)

participant

562˙290.00

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

FR (PARIS 15)

participant

489˙016.00

Project objective

Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.

Deliverables

List of deliverables.
Launch of the website	Websites, patent fillings, videos etc.	2019-05-30 15:16:10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZIKAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZIKAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)